Sosei Group Corporation is a holding company primarily engaged in the biopharmaceutical business. The Company is mainly involved in the research, development and sale of pharmaceutical drugs, including NVA237 and QVA149, used for chronic obstructive pulmonary disease; SO - 1105, used for oral thrush. As of March 31, 2013, the Company had three consolidated subsidiaries.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company